Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence

Pharmacogenomics

Volumn 9, Issue 6, 2008, Pages 655-658

  Anton, Raymond F ^a  

^a Center for Drug and Alcohol Programs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ASPARAGINE; ASPARTIC ACID; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO; NARCOTIC ANTAGONIST;

ALCOHOL ABSTINENCE; ALCOHOLISM; AMINO ACID SUBSTITUTION; BEHAVIOR THERAPY; CLINICAL TRIAL; DRUG RECEPTOR BINDING; DRUG RESPONSE; EDITORIAL; GENOTYPE; HUMAN; INCIDENCE; PREDICTION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; TREATMENT OUTCOME;

ALCOHOLISM; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; TREATMENT OUTCOME;

EID: 48949119319     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.6.655     Document Type: Editorial

References (26)

1. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC. Pickering RP: The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 74, 223-234 (2004).
2. Mason BJ: Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J. Clin. Psychiatry 62, 42-48 (2001).
3. Johnson BA. Rosenthal N. Capece JA et al.: Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298, 1641-1651 (2007).
4. Kranzler HR, van Kirk J: Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res. 25, 1335-1341 (2001).
5. Bouza C, Angoles M, Munoz A. Amate JM: Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99, 811-828 (2004).
6. Srisurapanont M, Jarusuralsin N: Naltrexone for the treatment of alcoholism a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 8, 267-280 (2005).
7. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ: Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl.) 160, 19-29 (2002).
8. Jaffe AJ, Rounsaville B, Chang G. Schottenfeld RS, Meyer R F, O'Malley SS: Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J. Consult. Clin. Psychol. 64, 1044-1053 (1996).
9. Monterosso JR, Flannery BA, Pettinati HM et al.: Predicting treatment response to naltrexone: the influence of craving and family history. Am. J. Addict. 10, 258-268 (2001).
10. Rubio G, Ponce G, Rodriguez-Jimenez R. Jimenez-Arriero MA, Hoenicka J, Palomo T: Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol. 40, 227-233 (2005).
11. Garbutt J, Kranzler H, O'Matley S et al.: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA 293, 1617-1625 (2005).
12. Bond C, LaForge KS, Tian M et al. Single-nucleotide polymorphism in the human μ oploid receptor gene alters f-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608-9613 (1998).
13. Beyer A, Koch T, Schroder H, Schulz S, Hollt V: Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human μ-opioid receptor. J. Neurochem. 89, 553-560 (2004).
14. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W: Allelic expression imbalance of human μ opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280, 32618-32624 (2005).
15. Ray LA, Hutchinson KE: A polymorphism of the μ-opioid receptor gene ( OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol. Clin. Exp. Res. 28, 1789-1795 (2004).
16. van den Wildenberg E, Wiers RW, Dessers J et al.: A functional polymorphism of the μ-opioid receptor gene, (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol. Clin. Exp. Res. 31, 1-10 (2007).
17. Lötsch J, Stuck B, Hummel T: The human μ-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation. Behav. Neurosci. 120, 1218-1224 (2006).
18. Wand GS, McCaul M, Yang X et al.: The μ-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26, 106-114 (2002).
19. Oslin DW, Berrettini W, Kranzler HR et al.: A functional polymorphism on the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28, 1546-1552 (2003).
20. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, The Veterans Affairs Naltrexone Cooperative 425 Study Group: naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 345, 1734-1739 (2001).
21. Gelernter J, Gueorguieva R, Kranzler HR et al.: Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA cooperative study. Alcohol. Clin. Exp. Res. 31, 555-563 (2007).
22. Anton RF, O'Malley SS, Ciraulo DA et al.: Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295, 2003-2017 (2006).
23. Anton R, Oroszi G, O'Malley SS et al.: An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch. Gen. Psychiatry 65, 135-144 (2008).
24. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K: Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch. Gen. Psychiatry 65, 466-475 (2008).
25. Anton RF, Drobes DJ, Voronin, K. Durazo-Avizu R, Moak D: Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl.) 173, 32-40 (2004).
26. Rist F, Randall CL, Heather N, Mann K: New developments in alcoholism treatment research in Europe. Alcohol. Clin. Exp. Res. 29, 1127-1132 (2005).